2023 World Conference on Lung Cancer (Posters)-P2.12. Treatment Patterns and Clinical Outcomes in Patients with EGFR-mutant NSCLC after Progression on First-Line Osimertinib

P2.12. Treatment Patterns and Clinical Outcomes in Patients with EGFR-mutant NSCLC after Progression on First-Line Osimertinib - PDF(Slides)

Back to course

Pdf Summary

A retrospective analysis was conducted using the Flatiron Health advanced NSCLC database to investigate treatment patterns and clinical outcomes in patients with EGFR-mutated NSCLC after progression on first-line osimertinib. The study included 541 patients who received second-line treatment, including chemotherapy, TKIs, and checkpoint inhibitors. Among the patients with PS 0-2, 32% received chemotherapy plus a TKI (continuing osimertinib) and 68% received chemotherapy without a TKI. The study found that continuing an EGFR TKI with chemotherapy in the second line setting was associated with improved progression-free survival (PFS) and overall survival (OS) compared to chemotherapy alone. In a subgroup analysis, patients with Exon 19 deletions had improved PFS and OS with the addition of a TKI, while those with L858R mutations only had improved PFS. Patients in an academic setting were more likely to receive a TKI along with second-line chemotherapy compared to those in a community practice. The study suggests that continuing a TKI with chemotherapy after progression on osimertinib may be beneficial. However, these results need to be confirmed in a prospective trial. The median PFS was 10.3 months for patients who continued a TKI with chemotherapy, compared to 6.0 months for those who did not continue a TKI. The median OS was 17.0 months for the TKI group and 13.0 months for the non-TKI group. Patients with Exon 19 deletions had a median PFS of 8.8 months with a TKI and 4.7 months without a TKI, while those with L858R mutations had a median PFS of 15.3 months with a TKI and 15.7 months without a TKI.

Asset Subtitle

Sarah Goldberg

Meta Tag

Speaker Sarah Goldberg

Topic Metastatic NSCLC: Targeted Therapy - Other

Keywords

retrospective analysis

NSCLC database

treatment patterns

clinical outcomes

EGFR-mutated NSCLC

osimertinib progression

second-line treatment

chemotherapy

TKIs

checkpoint inhibitors